Develops biologic immunomodulators for interstitial lung disease.
Dec 2025Revenue $190K/yrExpenses $77.8M/yr
No trendCash runway ≈ 1.0 years from Jun 2026
Figures by year
When will aTYR PHARMA be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $190K and expenses $77.8M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $190K | $77.8M | −$77.6M |
| Dec 2024 | $235K | $68.1M | −$67.9M |
| Dec 2023 | $353K | $55.3M | −$54.9M |
| Dec 2022 | $10.4M | $56.8M | −$46.4M |
| Dec 2021 | $0.00 | $34.0M | −$34.0M |
| Dec 2020 | $10.5M | $26.4M | −$15.9M |
| Dec 2019 | $422K | $23.4M | −$23.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.